Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Anteris Technologies Global Corp. ( (AVR) ) just unveiled an update.
On September 4, 2025, Anteris Technologies Global Corp. announced the postponement of its Special Meeting of Stockholders, originally scheduled for September 4, to September 11, 2025. The delay aims to provide stockholders additional time to vote, facilitating broader participation. The company’s Board of Directors recommends voting in favor of the proposals in the Proxy Statement filed with the SEC on August 18, 2025.
The most recent analyst rating on (AVR) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on Anteris Technologies Global Corp. stock, see the AVR Stock Forecast page.
Spark’s Take on AVR Stock
According to Spark, TipRanks’ AI Analyst, AVR is a Neutral.
Anteris Technologies Global Corp. has a low overall stock score due to significant financial challenges, including declining revenues and persistent losses. The technical analysis indicates a bearish trend, and the valuation is unattractive with a negative P/E ratio. However, the recent ASX waiver for securities issuance is a positive corporate event, providing potential strategic opportunities.
To see Spark’s full report on AVR stock, click here.
More about Anteris Technologies Global Corp.
Anteris Technologies Global Corp. is a global structural heart company focused on designing, developing, and commercializing innovative medical devices to restore healthy heart function. Founded in Australia with a significant presence in Minneapolis, USA, the company is known for its lead product, the DurAVR® Transcatheter Heart Valve, designed to treat aortic stenosis using its patented anti-calcification tissue technology.
Average Trading Volume: 197,909
Technical Sentiment Signal: Hold
Current Market Cap: $148.2M
For detailed information about AVR stock, go to TipRanks’ Stock Analysis page.